CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Second Quarter & Recent Corporate Highlights Clinical Pipeline Progress NEO100-01 – Intranasal therapy ...

Quazar Chairman and Executive Team with NeOnc's Executive's and Directors at Quazar's Headquarters in Dubai. CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed ...

CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled "AI and Biotech Take on Brain Cancer." This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sectio ...

Core Insights - NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to establish a new investment and clinical platform in the MENA region [1][2] - The partnership aims to leverage the UAE's clinical trial infrastructure to advance NeOnc's late-stage drug candidates [3][7] Investment and Structure - The term sheet outlines the formation of NuroMENA Holdings Ltd, which will oversee the establishment of NuroCure, an Abu Dhabi-based subsidiary responsible for clinical trials [2][5] - A proposed equity investment of $50 million is contingent upon NeOnc meeting specific conditions within 120 days [4][8] Clinical Development - NuroCure will initiate clinical trials for NEO100 and NEO212, targeting aggressive brain cancers such as Diffuse Intrinsic Pontine Glioma and glioblastoma multiforme [7][9] - The partnership is positioned to enhance NeOnc's clinical programs through collaboration with Cleveland Clinic Abu Dhabi [3][10] Financial Strategy - Quazar will lead a capital formation round of up to $50 million, with 70% allocated for acquiring NeOnc common stock and 30% for clinical trial and infrastructure development [8][10] - The investment strategy includes executing a Sub-License Agreement for NEO100 and NEO212, facilitating clinical efforts in the region [5][11] Company Background - NeOnc Technologies is focused on developing therapeutics for central nervous system cancers, with a robust patent portfolio extending to 2038 [11] - The company's drug candidates, NEO100 and NEO212, are currently in Phase II clinical trials under FDA Fast-Track status [11]

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as Chief Clinical Officer to enhance its clinical development strategy and accelerate clinical trials, particularly for its lead asset NEO100, which is nearing completion of Phase 2a ahead of schedule [1][5]. Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on innovative therapies for central nervous system cancers, with lead programs including NEO100 and NEO212 designed to bypass the blood-brain barrier [6]. Leadership Appointment - Dr. Neman joins from the Keck School of Medicine at USC, where he has significant experience in cancer neuroscience and has led various cancer research initiatives [2][3]. - His expertise in brain tumor biology and clinical leadership is expected to be instrumental in advancing NeOnc's mission to improve treatment outcomes for patients with life-threatening cancers [5]. Clinical Trials and Development - NeOnc is currently conducting four clinical trials, with NEO100's Phase 2a trial achieving full enrollment ahead of schedule [5]. - The company aims to integrate AI and quantum computing into its drug delivery platform, enhancing its precision therapies [5]. Research and Innovation - NeOnc's proprietary formulations and extensive patent portfolio (176 patents worldwide) reflect its strong potential for commercialization in the CNS cancer treatment market [6].